TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Apellis Pharmaceuticals, Inc.
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.

Insights
DIS   neutral

Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications

APLS   positive

Strong commercial execution with $689M in 2025 revenues, SYFOVRE achieving 60% market leadership with 17% YoY growth, EMPAVELI exceeding 5% market penetration in just 5 months post-launch, rapid payer uptake at 95%, positive Phase 3 data published in NEJM, pipeline expansion into additional indications (FSGS, DGF), and sufficient cash position ($466M) to fund operations to profitability.

Keywords
#SYFOVRE #EMPAVELI #geographic atrophy #C3G #IC-MPGN #complement inhibitor #clinical trial #FDA approval #revenue growth #market penetration

Tickers
APLS
← Prev: Markets Week Ahead: Key Bank Earnings, Inflation Data Take Center Stage